BSGM

BioSig Technologies, Inc. is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. The company is headquartered in Westport, Connecticut and currently employs 5 full-time employees. The company went IPO on 2014-09-22. The firm has an advanced digital signal processing technology platform, the PURE EP Platform (PURE EP), that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias. PURE EP is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise from other equipment, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP is a signal processing platform that combines advanced hardware and software to address known challenges associated to signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time. PURE EP is designed to enhance clinical decision-making and improve clinical workflows for all types of arrhythmias, even the challenging procedures for cardiac arrhythmias, like ventricular tachycardia and atrial fibrillation.